Watch and listen as Nezam H. Afdhal, MD, FRCPI, reviews the key clinical data on hepatitis B investigational and approved agents presented at the 2008 AASLD meeting.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recount recent data on novel therapies for the treatment of chronic hepatitis B
- Discuss new findings on the efficacy of US Food and Drug Administration–approved agents for the treatment of patients with chronic hepatitis B
- Describe new data on management strategies for treatment-naive hepatitis B patients
- Recount recent insights into the management of patients with drug-resistant hepatitis B virus infection or suboptimal response